Second, to make new predictions, we determined whether any of 1856 pan-cancer genes, significantly and concordantly deleted in tumors [41], could also play a role of biomarkers for the pair BRCA1, PARP1. To this end, for each gene G we applied SurvLRT to test the conditional epistases of type a and type b for the triple BRCA1, PARP1, G. As potential biomarkers we considered, as in the case of TP53BP1, such G for which type a was significant negative and type b was insignificant, after correction for false discoveries (Methods). The gene discussed is TP53BP1; the disease is cancer.